Concepts (240)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 28 | 2023 | 2036 | 1.350 |
Why?
|
| Neurons | 16 | 2014 | 332 | 1.240 |
Why?
|
| Cognition Disorders | 16 | 2010 | 957 | 1.210 |
Why?
|
| Hippocampus | 7 | 2018 | 266 | 0.830 |
Why?
|
| Nerve Growth Factor | 4 | 2012 | 43 | 0.690 |
Why?
|
| Amyloid beta-Peptides | 6 | 2018 | 309 | 0.640 |
Why?
|
| Choline O-Acetyltransferase | 8 | 2005 | 21 | 0.620 |
Why?
|
| Immunohistochemistry | 17 | 2009 | 368 | 0.610 |
Why?
|
| Nerve Tissue Proteins | 6 | 2004 | 153 | 0.420 |
Why?
|
| Peptide Fragments | 2 | 2014 | 75 | 0.410 |
Why?
|
| Basal Nucleus of Meynert | 3 | 2002 | 10 | 0.410 |
Why?
|
| Protein Precursors | 1 | 2012 | 20 | 0.400 |
Why?
|
| MAP Kinase Signaling System | 1 | 2012 | 37 | 0.390 |
Why?
|
| RNA, Messenger | 3 | 2004 | 306 | 0.380 |
Why?
|
| Cognitive Dysfunction | 4 | 2022 | 990 | 0.380 |
Why?
|
| Aged, 80 and over | 24 | 2015 | 4641 | 0.370 |
Why?
|
| Entorhinal Cortex | 4 | 2007 | 32 | 0.360 |
Why?
|
| Central Nervous System | 2 | 2003 | 52 | 0.360 |
Why?
|
| Animal Experimentation | 1 | 2010 | 3 | 0.350 |
Why?
|
| Frontal Lobe | 6 | 2022 | 78 | 0.350 |
Why?
|
| Dopamine | 6 | 2007 | 82 | 0.350 |
Why?
|
| F2-Isoprostanes | 1 | 2010 | 6 | 0.330 |
Why?
|
| Aged | 29 | 2015 | 8732 | 0.320 |
Why?
|
| Substantia Nigra | 5 | 2006 | 119 | 0.320 |
Why?
|
| Animals | 16 | 2018 | 3503 | 0.320 |
Why?
|
| Female | 30 | 2018 | 14734 | 0.310 |
Why?
|
| Male | 32 | 2018 | 14277 | 0.290 |
Why?
|
| Humans | 40 | 2023 | 25967 | 0.280 |
Why?
|
| Corpus Striatum | 5 | 2010 | 65 | 0.280 |
Why?
|
| Prosencephalon | 3 | 2005 | 8 | 0.280 |
Why?
|
| Brain-Derived Neurotrophic Factor | 3 | 1996 | 45 | 0.280 |
Why?
|
| Down-Regulation | 3 | 2002 | 99 | 0.270 |
Why?
|
| Peptides | 3 | 2018 | 100 | 0.260 |
Why?
|
| Macaca mulatta | 4 | 2010 | 58 | 0.260 |
Why?
|
| Cerebral Cortex | 4 | 2008 | 151 | 0.260 |
Why?
|
| Nerve Degeneration | 2 | 2009 | 48 | 0.250 |
Why?
|
| Membrane Transport Proteins | 2 | 2003 | 53 | 0.240 |
Why?
|
| Neuropsychological Tests | 12 | 2009 | 1150 | 0.230 |
Why?
|
| Bromodeoxyuridine | 1 | 2004 | 10 | 0.230 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2004 | 6 | 0.230 |
Why?
|
| Receptor, trkA | 2 | 2001 | 12 | 0.220 |
Why?
|
| Cell Proliferation | 1 | 2004 | 173 | 0.220 |
Why?
|
| Nerve Growth Factors | 3 | 1999 | 37 | 0.210 |
Why?
|
| Parkinson Disease | 6 | 2010 | 640 | 0.210 |
Why?
|
| Neurodegenerative Diseases | 2 | 2009 | 123 | 0.200 |
Why?
|
| Receptor, Nerve Growth Factor | 2 | 2002 | 10 | 0.200 |
Why?
|
| Insulins | 1 | 2022 | 4 | 0.200 |
Why?
|
| Tyrosine 3-Monooxygenase | 6 | 2010 | 52 | 0.200 |
Why?
|
| Acetylcholine | 1 | 2002 | 7 | 0.190 |
Why?
|
| Aging | 7 | 2009 | 1483 | 0.190 |
Why?
|
| Brain Mapping | 3 | 2022 | 145 | 0.190 |
Why?
|
| Axonal Transport | 2 | 1999 | 6 | 0.180 |
Why?
|
| Disease Models, Animal | 6 | 2018 | 577 | 0.170 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2001 | 24 | 0.170 |
Why?
|
| Mice, Transgenic | 4 | 2018 | 214 | 0.170 |
Why?
|
| tau Proteins | 5 | 2010 | 225 | 0.170 |
Why?
|
| Brain | 4 | 2022 | 1569 | 0.170 |
Why?
|
| Cholinergic Fibers | 3 | 2005 | 9 | 0.160 |
Why?
|
| Cell Count | 4 | 2006 | 80 | 0.160 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2018 | 21 | 0.150 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2018 | 36 | 0.140 |
Why?
|
| Genetic Therapy | 2 | 2010 | 84 | 0.140 |
Why?
|
| Limbic System | 1 | 1996 | 7 | 0.130 |
Why?
|
| Neuronal Plasticity | 3 | 2014 | 48 | 0.130 |
Why?
|
| Mice | 4 | 2018 | 1352 | 0.130 |
Why?
|
| Neostriatum | 1 | 1996 | 14 | 0.120 |
Why?
|
| Substantia Innominata | 2 | 2009 | 5 | 0.120 |
Why?
|
| Genotype | 3 | 2002 | 339 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2022 | 1059 | 0.110 |
Why?
|
| Nootropic Agents | 1 | 2015 | 14 | 0.110 |
Why?
|
| Dendrites | 1 | 2014 | 9 | 0.110 |
Why?
|
| CA1 Region, Hippocampal | 1 | 2014 | 9 | 0.110 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2014 | 4 | 0.110 |
Why?
|
| Gyrus Cinguli | 1 | 2014 | 14 | 0.110 |
Why?
|
| Pyramidal Cells | 1 | 2014 | 35 | 0.110 |
Why?
|
| Statistics, Nonparametric | 3 | 2010 | 117 | 0.110 |
Why?
|
| Memory Disorders | 1 | 2015 | 154 | 0.100 |
Why?
|
| Transcription Factors | 2 | 2006 | 162 | 0.100 |
Why?
|
| Stem Cells | 2 | 2004 | 37 | 0.100 |
Why?
|
| Rats | 4 | 2002 | 640 | 0.100 |
Why?
|
| Disease Progression | 5 | 2022 | 655 | 0.100 |
Why?
|
| DNA-Binding Proteins | 2 | 2006 | 268 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 3 | 1999 | 320 | 0.100 |
Why?
|
| Apoptosis | 1 | 2012 | 209 | 0.090 |
Why?
|
| Ubiquitin | 3 | 2009 | 32 | 0.090 |
Why?
|
| Macaca fascicularis | 2 | 2004 | 25 | 0.090 |
Why?
|
| Presenilin-1 | 1 | 2010 | 8 | 0.090 |
Why?
|
| Gels | 1 | 2010 | 11 | 0.090 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 22 | 0.090 |
Why?
|
| Nitriles | 1 | 2010 | 13 | 0.090 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2010 | 16 | 0.090 |
Why?
|
| Mass Spectrometry | 1 | 2010 | 33 | 0.090 |
Why?
|
| Receptors, Nerve Growth Factor | 2 | 2002 | 10 | 0.090 |
Why?
|
| MPTP Poisoning | 1 | 2010 | 15 | 0.090 |
Why?
|
| Triazoles | 1 | 2010 | 29 | 0.090 |
Why?
|
| Neurturin | 1 | 2010 | 22 | 0.090 |
Why?
|
| Administration, Oral | 1 | 2010 | 104 | 0.090 |
Why?
|
| Antipsychotic Agents | 1 | 2010 | 53 | 0.080 |
Why?
|
| Body Weight | 1 | 2010 | 132 | 0.080 |
Why?
|
| Amnesia | 1 | 2009 | 21 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2003 | 90 | 0.080 |
Why?
|
| Presynaptic Terminals | 2 | 2023 | 11 | 0.080 |
Why?
|
| Huntington Disease | 1 | 2009 | 45 | 0.080 |
Why?
|
| Environment | 1 | 2009 | 40 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 649 | 0.070 |
Why?
|
| Cognition | 2 | 2014 | 1250 | 0.070 |
Why?
|
| Neuropil Threads | 3 | 2007 | 7 | 0.070 |
Why?
|
| Carbon-Nitrogen Lyases | 1 | 2008 | 3 | 0.070 |
Why?
|
| Middle Aged | 8 | 2015 | 8772 | 0.070 |
Why?
|
| Autopsy | 3 | 2009 | 334 | 0.070 |
Why?
|
| Caspase 6 | 1 | 2007 | 8 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2007 | 114 | 0.070 |
Why?
|
| Brain Chemistry | 1 | 2007 | 42 | 0.070 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 2006 | 21 | 0.060 |
Why?
|
| Infusions, Parenteral | 2 | 1996 | 10 | 0.060 |
Why?
|
| Plaque, Amyloid | 2 | 2007 | 143 | 0.060 |
Why?
|
| Recombinant Proteins | 2 | 1996 | 178 | 0.060 |
Why?
|
| Visual Cortex | 1 | 2005 | 5 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2004 | 132 | 0.050 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2004 | 20 | 0.050 |
Why?
|
| Estradiol | 1 | 2004 | 53 | 0.050 |
Why?
|
| Ovariectomy | 2 | 2004 | 26 | 0.050 |
Why?
|
| Myelin Basic Protein | 1 | 2004 | 23 | 0.050 |
Why?
|
| Neurofibrillary Tangles | 4 | 2007 | 186 | 0.050 |
Why?
|
| Vesicular Glutamate Transport Proteins | 1 | 2023 | 2 | 0.050 |
Why?
|
| Vesicular Glutamate Transport Protein 2 | 1 | 2023 | 2 | 0.050 |
Why?
|
| Vesicular Glutamate Transport Protein 1 | 1 | 2023 | 5 | 0.050 |
Why?
|
| Analysis of Variance | 3 | 2009 | 252 | 0.050 |
Why?
|
| Propionates | 1 | 2002 | 11 | 0.050 |
Why?
|
| Quinolinic Acid | 1 | 2002 | 11 | 0.050 |
Why?
|
| Neurotoxins | 1 | 2002 | 13 | 0.050 |
Why?
|
| Parahippocampal Gyrus | 1 | 2002 | 5 | 0.050 |
Why?
|
| Parietal Lobe | 1 | 2002 | 17 | 0.050 |
Why?
|
| Causality | 1 | 2002 | 55 | 0.050 |
Why?
|
| Neuroglia | 1 | 2002 | 47 | 0.050 |
Why?
|
| Temporal Lobe | 1 | 2002 | 87 | 0.050 |
Why?
|
| Gene Expression Regulation | 3 | 2010 | 266 | 0.040 |
Why?
|
| Neurobehavioral Manifestations | 1 | 2000 | 2 | 0.040 |
Why?
|
| Atrophy | 1 | 2001 | 83 | 0.040 |
Why?
|
| Mesencephalon | 2 | 2007 | 23 | 0.040 |
Why?
|
| Injections, Intraventricular | 2 | 1999 | 8 | 0.040 |
Why?
|
| Organ Specificity | 1 | 1999 | 40 | 0.040 |
Why?
|
| Estrogen Receptor alpha | 1 | 1999 | 16 | 0.040 |
Why?
|
| Vesicular Transport Proteins | 1 | 1999 | 10 | 0.040 |
Why?
|
| Catholicism | 1 | 1999 | 19 | 0.040 |
Why?
|
| Age Factors | 1 | 2002 | 757 | 0.040 |
Why?
|
| Synaptophysin | 2 | 2009 | 9 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 1999 | 64 | 0.040 |
Why?
|
| Fibroblast Growth Factors | 1 | 1999 | 6 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 1999 | 96 | 0.040 |
Why?
|
| Neuroprotective Agents | 1 | 1999 | 50 | 0.040 |
Why?
|
| Apolipoproteins E | 1 | 1999 | 235 | 0.040 |
Why?
|
| Occipital Lobe | 1 | 1996 | 6 | 0.030 |
Why?
|
| Biological Transport | 1 | 1996 | 39 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 1996 | 49 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 2 | 2008 | 174 | 0.030 |
Why?
|
| Inflammation | 1 | 2018 | 267 | 0.030 |
Why?
|
| Injections | 1 | 1996 | 42 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2014 | 512 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2018 | 437 | 0.030 |
Why?
|
| Dementia | 1 | 2000 | 524 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2009 | 159 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 2015 | 28 | 0.030 |
Why?
|
| Turkeys | 1 | 1994 | 1 | 0.030 |
Why?
|
| Receptors, AMPA | 1 | 2014 | 7 | 0.030 |
Why?
|
| Solubility | 1 | 2014 | 26 | 0.030 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 2 | 2006 | 12 | 0.030 |
Why?
|
| Antibodies | 1 | 1994 | 45 | 0.030 |
Why?
|
| Axons | 1 | 2014 | 28 | 0.030 |
Why?
|
| Synapses | 1 | 2014 | 34 | 0.030 |
Why?
|
| Models, Animal | 1 | 2014 | 110 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 31 | 0.030 |
Why?
|
| alpha-Synuclein | 2 | 2006 | 119 | 0.030 |
Why?
|
| United States | 1 | 1999 | 1989 | 0.030 |
Why?
|
| Tissue Extracts | 1 | 1993 | 9 | 0.030 |
Why?
|
| Adult | 3 | 2015 | 7662 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 868 | 0.020 |
Why?
|
| Phenotype | 2 | 2002 | 290 | 0.020 |
Why?
|
| Dependovirus | 1 | 2010 | 39 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2010 | 61 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2009 | 103 | 0.020 |
Why?
|
| Gliosis | 1 | 2009 | 7 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2005 | 1333 | 0.020 |
Why?
|
| CD8 Antigens | 1 | 2009 | 11 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2009 | 61 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 2009 | 29 | 0.020 |
Why?
|
| Oleanolic Acid | 1 | 2009 | 6 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2009 | 43 | 0.020 |
Why?
|
| Adolescent | 2 | 2007 | 2099 | 0.020 |
Why?
|
| Graft Survival | 1 | 2009 | 96 | 0.020 |
Why?
|
| Neocortex | 1 | 2009 | 31 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2009 | 296 | 0.020 |
Why?
|
| Biomarkers | 2 | 2002 | 544 | 0.020 |
Why?
|
| Transglutaminases | 1 | 2008 | 5 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 2008 | 11 | 0.020 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 2007 | 18 | 0.020 |
Why?
|
| Apolipoprotein E4 | 1 | 2009 | 251 | 0.020 |
Why?
|
| Amyloid | 1 | 2008 | 54 | 0.020 |
Why?
|
| Binding Sites | 1 | 2007 | 71 | 0.020 |
Why?
|
| Isoprostanes | 1 | 2007 | 2 | 0.020 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2007 | 11 | 0.020 |
Why?
|
| Immunoassay | 1 | 2007 | 37 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2007 | 118 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2007 | 408 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2006 | 33 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2006 | 30 | 0.020 |
Why?
|
| Reference Values | 1 | 2006 | 181 | 0.020 |
Why?
|
| Histological Techniques | 1 | 2005 | 6 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2005 | 56 | 0.010 |
Why?
|
| Motor Activity | 1 | 2007 | 317 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2005 | 36 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2005 | 84 | 0.010 |
Why?
|
| Synucleins | 1 | 2004 | 8 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2004 | 55 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 2004 | 99 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2004 | 145 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 137 | 0.010 |
Why?
|
| Child | 1 | 2007 | 1217 | 0.010 |
Why?
|
| Synaptic Transmission | 1 | 2002 | 24 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2002 | 55 | 0.010 |
Why?
|
| Nitro Compounds | 1 | 2002 | 9 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2002 | 21 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 106 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 2002 | 34 | 0.010 |
Why?
|
| Silver Staining | 1 | 2002 | 4 | 0.010 |
Why?
|
| Cell Size | 1 | 2001 | 7 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 328 | 0.010 |
Why?
|
| Linear Models | 1 | 2002 | 240 | 0.010 |
Why?
|
| Chemical Fractionation | 1 | 2000 | 6 | 0.010 |
Why?
|
| Lewy Bodies | 1 | 2002 | 185 | 0.010 |
Why?
|
| Disability Evaluation | 1 | 2001 | 255 | 0.010 |
Why?
|
| Vesicular Acetylcholine Transport Proteins | 1 | 1999 | 2 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1999 | 31 | 0.010 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 1999 | 26 | 0.010 |
Why?
|
| Time Factors | 1 | 2002 | 1391 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2002 | 1701 | 0.010 |
Why?
|
| Caudate Nucleus | 1 | 1993 | 11 | 0.010 |
Why?
|
| Cell Division | 1 | 1993 | 82 | 0.010 |
Why?
|
| Putamen | 1 | 1993 | 19 | 0.010 |
Why?
|
| Cerebellum | 1 | 1993 | 39 | 0.010 |
Why?
|